BusinessTempus and Cleveland Clinic Collaborate on Personalized Medicine InitiativeBy Nasdaq OMXSep 14, 2017, 2:30 PM UTC
BusinessCrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck CancerBy Nasdaq OMXSep 13, 2017, 2:04 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXSep 11, 2017, 8:05 PM UTC
BusinessTESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual MeetingBy Nasdaq OMXSep 11, 2017, 12:01 PM UTC
BusinessNew Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune ResponseBy Nasdaq OMXSep 8, 2017, 8:00 AM UTC
BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 5, 2017, 8:05 PM UTC
